BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025)

BioAge Labs (BIOA) posted Non-Current Deffered Revenue of $556000.0 for Q3 2025, down 70.77% sequentially from $1.9 million in Q2 2025.

BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends

BioAge Labs has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $556000.0 in Q3 2025.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $556000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $556000.0 (changed N/A YoY) and the FY2024 annual result came in at $4.7 million, changed N/A from the prior year.
Non-Current Deffered Revenue eased to $556000.0 in Q3 2025 per BIOA's latest filing, from $1.9 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $4.7 million in Q4 2024 and troughed at $556000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn	-
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	-
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	-
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-	-
10	BioAge Labs	436.28 Mn	436.28 Mn	-14.23 Mn	-

Download Data